A Phase 3, Randomized, Open-Label, Study of Lopinavir/Ritonavir (LPV/r) [Kaletra] Tablets Versus Soft Gel Capsules (SGC) and Once Daily (QD) Versus Twice Daily (BID) Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral Naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects.

Trial Profile

A Phase 3, Randomized, Open-Label, Study of Lopinavir/Ritonavir (LPV/r) [Kaletra] Tablets Versus Soft Gel Capsules (SGC) and Once Daily (QD) Versus Twice Daily (BID) Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral Naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Feb 2012 Additional trial locations added as reported by ClinicalTrials.gov.
    • 01 Aug 2010 Final 96-week efficacy and tolerability results have been published in AIDS Research and Human Retroviruses.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top